Cognition Therapeutics, Inc. (CGTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -36.60M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 26.14M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-36.60M | (m) | (m) | $26.14M | (m) | (m) |
| 2026-03-31 | $-42.84M | (m) | (m) | $32.52M | (m) | (m) |
| 2025-12-31 | $-47.80M | (m) | (m) | $37.19M | (m) | (m) |
| 2025-09-30 | $-44.85M | (m) | (m) | $34.19M | (m) | (m) |
| 2025-06-30 | $-52.94M | (m) | (m) | $41.81M | (m) | (m) |
| 2025-03-31 | $-53.64M | (m) | (m) | $41.91M | (m) | (m) |
| 2024-12-31 | $-53.97M | (m) | (m) | $41.68M | (m) | (m) |
| 2024-09-30 | $-58.43M | (m) | (m) | $45.12M | (m) | (m) |
| 2024-06-30 | $-58.71M | (m) | (m) | $45.40M | (m) | (m) |
| 2024-03-31 | $-55.85M | (m) | (m) | $42.32M | (m) | (m) |
| 2023-12-31 | $-50.72M | (m) | (m) | $37.20M | (m) | (m) |
| 2023-09-30 | $-44.84M | (m) | (m) | $32.04M | (m) | (m) |
| 2023-06-30 | $-42.72M | (m) | (m) | $28.64M | (m) | (m) |
| 2023-03-31 | $-43.11M | (m) | (m) | $29.24M | (m) | (m) |
| 2022-12-31 | $-43.55M | (m) | (m) | $30.32M | (m) | (m) |
| 2022-09-30 | $-46.06M | (m) | (m) | $29.46M | (m) | (m) |
| 2022-06-30 | $-38.66M | (m) | (m) | $24.86M | (m) | (m) |
| 2022-03-31 | $-32.43M | (m) | (m) | $20.66M | (m) | (m) |
| 2021-12-31 | $-28.60M | (m) | (m) | $18.57M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-17.41M | (m) | (m) | $12.89M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |